Paysign Reports Record 2025 Financials with Near-Doubled Net Income and Strong Revenue Growth, Resolves Legal Actions

summarizeSummary

Paysign, Inc. reported record financial results for fiscal year 2025, with substantial growth in revenue, net income, and Adjusted EBITDA, alongside the strategic acquisition of Gamma Innovation LLC and the resolution of pending legal proceedings.

check_boxKey Events

• Record Revenue Growth

  Total revenues increased by 40.5% to $82.03 million for the year ended December 31, 2025, driven by significant growth in the pharma industry segment (up 167.8%).

• Net Income Nearly Doubles

  Net income surged by 97.9% to $7.55 million, and diluted EPS increased from $0.07 to $0.13, reflecting strong profitability improvements.

• Adjusted EBITDA Soars

  Adjusted EBITDA grew by 107.3% to $19.94 million, indicating enhanced operational efficiency and earnings power.

• Strategic Acquisition Completed

  The company completed the acquisition of Gamma Innovation LLC on March 19, 2025, for $15.56 million, expanding its life science technology solutions and market presence.

auto_awesomeAnalysis

Paysign, Inc. has delivered exceptionally strong financial results for fiscal year 2025, confirming the positive preliminary announcement from the prior day's 8-K. The significant growth across key metrics, including a 40.5% increase in total revenue and a near-doubling of net income and Adjusted EBITDA, indicates robust operational performance and successful expansion in its core markets. The acquisition of Gamma Innovation LLC further strengthens its life science technology solutions. Additionally, the resolution of multiple securities class action and stockholder derivative lawsuits removes a significant legal overhang, enhancing investor confidence. The company's strong liquidity position and positive outlook for the next 24 months underscore its financial health and growth trajectory.